Entero Therapeutics Regains Compliance with Nasdaq Equity Rule

Entero Therapeutics, Inc. has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement, as confirmed by a letter from Nasdaq on October 28, 2025. The company had previously disclosed non-compliance with the Equity Rule due to a stockholders' equity of ($3,876,738) as of December 31, 2024, which was below the required $2.5 million. Entero Therapeutics submitted a compliance plan and received an extension until October 8, 2025, to regain compliance. The company achieved compliance through a share exchange agreement with GridAI Corp, which was completed on September 30, 2025. Nasdaq has confirmed the company's compliance but noted that failure to evidence compliance in the next periodic report could result in delisting.